Indivior PLC (NASDAQ:INDV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Indivior PLC (NASDAQ:INDV) have received a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $40.2857.

INDV has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Finally, Barclays started coverage on shares of Indivior in a research note on Thursday, June 18th. They set an “overweight” rating and a $46.00 price objective for the company.

Indivior Stock Performance

INDV traded up $0.73 on Tuesday, hitting $40.73. 253,345 shares of the company were exchanged, compared to its average volume of 2,221,024. The firm has a fifty day simple moving average of $37.98 and a two-hundred day simple moving average of $34.87. Indivior has a 12 month low of $14.93 and a 12 month high of $42.81. The stock has a market capitalization of $4.97 billion, a PE ratio of 20.89 and a beta of 0.86.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The firm had revenue of $317.00 million during the quarter. On average, equities analysts expect that Indivior will post 4.05 earnings per share for the current year.

Insider Transactions at Indivior

In other Indivior news, CFO Ryan Preblick sold 36,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the transaction, the chief financial officer owned 284,751 shares of the company’s stock, valued at $10,735,112.70. This represents a 11.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Indivior

Hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. lifted its stake in Indivior by 18.4% in the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after acquiring an additional 1,299,425 shares during the period. Jane Street Group LLC raised its stake in Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock worth $9,327,000 after buying an additional 958,132 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Indivior by 669.1% in the second quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock worth $5,769,000 after buying an additional 340,498 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Indivior in the second quarter worth about $207,000. Finally, Walleye Capital LLC purchased a new stake in Indivior in the second quarter worth about $594,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.